AVTX Stock Overview
A clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Avalo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.33 |
| 52 Week High | US$34.46 |
| 52 Week Low | US$3.95 |
| Beta | 0.89 |
| 1 Month Change | -12.77% |
| 3 Month Change | -12.32% |
| 1 Year Change | -8.46% |
| 3 Year Change | -99.83% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007
Aug 01Avalo Therapeutics announces one-for-twelve reverse stock split
Jul 06Is Cerecor (NASDAQ:CERC) A Risky Investment?
Aug 10
Cerecor enters into $35M debt financing agreement with Horizon Technology Finance
Jun 07What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?
Mar 10Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?
Jan 18Armistice Capital adds 2.5M Cerecor shares for $6.5M
Jan 13Cerecor slumps 12% on stock and pre-funded warrants offering
Jan 07Shareholder Returns
| AVTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.5% | 0.7% | 0.6% |
| 1Y | -8.5% | -3.4% | 23.7% |
Return vs Industry: AVTX underperformed the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: AVTX underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| AVTX volatility | |
|---|---|
| AVTX Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AVTX's weekly volatility has decreased from 53% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 19 | Garry Neil | www.avalotx.com |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company’s drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases.
Avalo Therapeutics, Inc. Fundamentals Summary
| AVTX fundamental statistics | |
|---|---|
| Market cap | US$87.16m |
| Earnings (TTM) | -US$8.13m |
| Revenue (TTM) | US$820.00k |
106.3x
P/S Ratio-10.7x
P/E RatioIs AVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVTX income statement (TTM) | |
|---|---|
| Revenue | US$820.00k |
| Cost of Revenue | US$10.16m |
| Gross Profit | -US$9.34m |
| Other Expenses | -US$1.21m |
| Earnings | -US$8.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | -1,139.27% |
| Net Profit Margin | -992.07% |
| Debt/Equity Ratio | 0% |
How did AVTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 11:59 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avalo Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Louise Chen | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |